KP
AZN icon

Keel Point’s AstraZeneca AZN Stock Holding History

Keel Point’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$577K Buy
3,042
+214
+8% +$40.3K 0.03% 264
2026
Q1 		$558K Sell
2,828
-2,398
-46% -$462K 0.04% 258
2025
Q4 		$961K Sell
5,226
-142
-3% -$24.9K 0.06% 189
2025
Q3 		$824K Sell
5,368
-39
-0.7% -$5.9K 0.05% 214
2025
Q2 		$756K Buy
5,407
+2,142
+66% +$300K 0.05% 220
2025
Q1 		$480K Sell
3,265
-5
-0.2% -$723 0.04% 264
2024
Q4 		$428K Sell
3,270
-39
-1% -$5.46K 0.03% 262
2024
Q3 		$516K Buy
3,309
+4
+0.1% +$646 0.04% 233
2024
Q2 		$551K Buy
3,305
+391
+13% +$58.8K 0.05% 212
2024
Q1 		$395K Buy
2,914
+393
+16% +$52K 0.04% 242
2023
Q4 		$340K Buy
2,521
+68
+3% +$8.84K 0.04% 242
2023
Q3 		$332K Sell
2,453
-478
-16% -$65.3K 0.05% 223
2023
Q2 		$419K Sell
2,931
-214
-7% -$31.5K 0.06% 191
2023
Q1 		$437K Sell
3,145
-204
-6% -$27.4K 0.06% 176
2022
Q4 		$454K Buy
3,349
+309
+10% +$38.8K 0.07% 175
2022
Q3 		$333K Buy
3,040
+29
+1% +$3.68K 0.06% 177
2022
Q2 		$399K Buy
3,011
+344
+13% +$45.1K 0.06% 171
2022
Q1 		$354K Sell
2,667
-141
-5% -$16.9K 0.05% 187
2021
Q4 		$327K Buy
2,808
+76
+3% +$8.94K 0.04% 198
2021
Q3 		$328K Buy
2,732
+400
+17% +$46.6K 0.04% 189
2021
Q2 		$279K Sell
2,332
-526
-18% -$57.7K 0.03% 209
2021
Q1 		$284K Buy
+2,858
New +$287K 0.03% 208

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Keel Point's AZN Position: Q2 2026 in Review

Keel Point increased its AstraZeneca (AZN) stake by 7.6% in Q2 2026, buying an estimated $40.3K and bringing the position to 3,042 shares worth $577K. The position accounts for 0.03% of the portfolio, ranked #264.

Keel Point first reported a position in AZN in Q1 2021 and has held it in 22 quarters since. The position peaked at $961K in Q4 2025. 1,498 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Keel Point held 3,042 shares of AstraZeneca worth $577K as of Q2 2026.
  • Keel Point bought 214 AstraZeneca shares in Q2 2026, an estimated $40.3K.
  • AstraZeneca made up 0.03% of Keel Point's portfolio in Q2 2026, its #264 holding.
  • Keel Point first reported a position in AstraZeneca in Q1 2021 and has held it in 22 quarters since.
  • Keel Point's AstraZeneca position peaked at $961K in Q4 2025.
  • 1,498 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Keel Point's 13F filing for Q2 2026, filed 14 Aug 2026.